益髓生血颗粒联合羟基脲治疗中间型β地中海贫血  

Yisui Shengxue Granule Combined with Hydroxycarbamide in Treating Patients with Thalassemia Intermedia

作　　者：周亚丽[1] 李瑶芸 孔祥敬[1] 陈永升[1] 周天红[1] 尹晓林[1] 张新华[1] 

机构地区：[1]解放军303医院血液科,广西南宁530021

出　　处：《华南国防医学杂志》2015年第11期821-823,共3页Military Medical Journal of South China

基　　金：广西自然科学基金项目(2012GXNSFAA053156;2014GXNSFBA118187);国家重点基础研究发展计划("973")项目(2010CB530406)

摘　　要：目的评价中药益髓生血颗粒联合西药羟基脲治疗中间型β地中海贫血(thalassemia intermedia,TI)的临床疗效。方法 60例TI患者随机分成3组,分别口服益髓生血颗粒、口服羟基脲以及同时口服益髓生血颗粒和羟基脲3个月。治疗前后分别检测3组患者血红蛋白(hemoglobin,Hb)、胎儿血红蛋白(fetal hemoglobin,Hb F)、白细胞(white blood cell,WBC),并记录不良反应。结果 57例按试验方案完成治疗和检查,联合用药组Hb和Hb F升高程度优于益髓生血颗粒组和羟基脲组(P<0.05),3组WBC改变无明显差异。结论益髓生血颗粒联合羟基脲进一步提升Hb和Hb F,使TI患者贫血症状减轻。Objective To evaluate the therapeutic effect of Yisui Shengxue Granule combined with hydroxycarbam- ide in treating patients with thalassemia intermedia （TI）. Method Sixty patients were recruited and randomly allocated into control group I （orally Yisui Shengxue Granule alone）, control group 2 （orally hydroxyurea alone）, and treatment group （orally Yisui Shengxue Granule conbined with hydroxyurea）.Trial was terminated after 3 months of treatment.Lev- els of hemoglobin （Hb）, fetal hemoglobin （HbF）, white blood cell （WBC） were detected before and after the treatment, and adverse reactions were recorded.Results Fifty-seven cases completed the protocol. In all three groups, levels of Hb and HBF but not WBC count increased significantly after treatment compared to the pre-treatment levels. However, incre- ment of Hb and HbF level were significantly higher in treatment group compared with control group 1 and control group 2 （P〈0.05）.Conclusion In patients with TI, combined prescribes of Yisui Shengxue Granule and hydroxyurea could fur- ther improve Hb and HbF levels and thus relieve symptoms of anemia.

关 键 词：Β地中海贫血 中间型 益髓生血颗粒 羟基脲 

分 类 号：R285.5[医药卫生—中药学]